CCL2 as a potential therapeutic target for clear cell renal cell carcinoma

详细信息    查看全文

• 作者：Ryuichiro Arakaki ; Toshinari Yamasaki ; Toru Kanno ; Noboru Shibasaki ; Hiromasa Sakamoto ; Noriaki Utsunomiya ; Takayuki Sumiyoshi ; Shinsuke Shibuya ; Tatsuaki Tsuruyama ; Eijiro Nakamura ; Osamu Ogawa and Tomomi Kamba
• 刊名：Cancer Medicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：5
• 期：10
• 页码：2920-2933
• 全文大小：528K
• ISSN：2045-7634

文摘

We previously reported that the pVHL-atypical PKC-JunB pathway contributed to promotion of cell invasiveness and angiogenesis in clear cell renal cell carcinoma (ccRCC), and we detected chemokine (C-C motif) ligand-2 (CCL2) as one of downstream effectors of JunB. CCL2 plays a critical role in tumorigenesis in other types of cancer, but its role in ccRCC remains unclear. In this study, we investigated the roles and therapeutic potential of CCL2 in ccRCC. Immunohistochemical analysis of CCL2 expression for ccRCC specimens showed that upregulation of CCL2 expression correlated with clinical stage, overall survival, and macrophage infiltration. For functional analysis of CCL2 in ccRCC cells, we generated subclones of WT8 cells that overexpressed CCL2 and subclones 786-O cells in which CCL2 expression was knocked down. Although CCL2 expression did not affect cell proliferation in vitro, CCL2 overexpression enhanced and CCL2 knockdown suppressed tumor growth, angiogenesis, and macrophage infiltration in vivo. We then depleted macrophages from tumor xenografts by administration of clodronate liposomes to confirm the role of macrophages in ccRCC. Depletion of macrophages suppressed tumor growth and angiogenesis. To examine the effect of inhibiting CCL2 activity in ccRCC, we administered CCL2 neutralizing antibody to primary RCC xenografts established from patient surgical specimens. Inhibition of CCL2 activity resulted in significant suppression of tumor growth, angiogenesis, and macrophage infiltration. These results suggest that CCL2 is involved in angiogenesis and macrophage infiltration in ccRCC, and that CCL2 could be a potential therapeutic target for ccRCC.